Pipeline
Our pipeline is designed to bring orally bioavailable drugs to better serve patients in the treatment of autoimmune disease

We are leveraging our proprietary DELSCAPE platform to design and develop a pipeline of wholly owned, oral, small molecule therapeutics against validated biologic targets to address chronic diseases in immunology and other therapeutic areas.

In collaboration with Sanofi, we are also developing a therapeutic candidate for immuno-oncology indications.

Program
IL-17
Psoriasis
Preclinical
Discovery
Phase 1
Progress
I/O Small Molecule
Discovery Program 1
Discovery Program 2
Discovery Program 3
GLOBAL
RIGHTS
Preclinical
Global Rights: DiCE
Preclinical
Global Rights: Sanofi
Discovery
Global Rights: DiCE
Discovery
Global Rights: DiCE
Discovery
Global Rights: DiCE